RB (formerly called Reckitt Benckiser) is the world’s leading consumer health and hygiene company. The company has operations in over 60 countries, with headquarters in the UK, Singapore, Dubai and Amsterdam, and sales in almost 200 countries. The company employs approximately 37,000 people worldwide and generated revenues of £ 11.5 billion in 2017. With a purpose of delivering innovative solutions for healthier lives and happier homes, RB is in the top 20 of companies listed on the London Stock Exchange. Its health, hygiene and home portfolio is led by 19 global Powerbrands including Mucinex, Durex, Scholl, Lysol, Clearasil, Veet, Finish, Air Wick, French’s, Nurofen, Strepsils, Gaviscon, Dettol, Harpic, Bang, Woolite, Mortein, Vanish and Calgon.
In their annual Sustainability Reports, RB made a commitment of helping over 400 million improve their health and hygiene by 2020 and has prioritised the United Nations Sustainable Development Goals on eliminating hunger, improving health and well-being, promoting gender equality, and expanding clean water and sanitation.
Note: Proceeds are funds made available to Gavi from donor contributions and commitments, either through cash payments made to Gavi, through frontloading via the capital markets of a future donor commitment to IFFIm, or through AMC funds released to Gavi via the World Bank. IFFIm proceeds are allocated over five year periods coinciding with Gavi’s strategic periods. Proceeds for the current and future strategic periods are indicative until the end of each period and could be revised following changes in market conditions (interest rates or foreign exchange rates), the signing of new pledge(s) and/or changes in IFFIm’s disbursement profile.
Click on Direct, IFFIm, AMC or Matching Fund in the above key to toggle their data on the graph, click again to show the data
Direct Contributions (including Matching Fund)
Received contributions: non-US$ contributions for 2000-2018 and Q1-Q3 2019 are expressed in US$ equivalents using the exchange rates on the dates of receipt. For 2014-2018 and Q1-Q3 2019, where contributions were hedged to mitigate currency risk exposure, these have been expressed using the rates applicable to the hedge agreement.
Future contributions: non-US$ Direct Contribution and Matching Fund pledges for Q4 2019 and years 2020 and beyond are expressed in US$ equivalents using the applicable 'forecast rates' from Bloomberg as at 30 September 2019 or using the rates applicable to any hedge agreement in place.
Received contributions: non-US$ contributions for 2000-2018 and Q1-Q3 2019 are expressed in US$ equivalents as confirmed by the IBRD (World Bank)
Future contributions: non-US$ contributions for Q4 2019 and years 2020 and beyond are expressed in US$ equivalents as follows:
Where the contribution agreement has been signed: contributions are expressed in US$ equivalents using the exchange rates at the time of signing the respective donor grant agreements
Where the contribution agreement has not yet been signed: contributions are expressed in US$ equivalents using the applicable 'forecast rates' from Bloomberg as at 30 September 2019
While IFFIm grants are irrevocable and legally binding, they are subject to a Grant Payment Condition that can potentially reduce the amount due in the event that a programme country is in protracted arrears with the International Monetary Fund. As of 30 September 2019, IFFIm donor grant payments are reduced by 1.5%, however such reductions are not reflected in future contributions figures.
RB committed USD 1.4 million (matched by the Gavi Matching Fund) to directly fund the introduction and scale-up of the rotavirus vaccination programme in Pakistan. The vaccine protects against rotavirus disease, the leading cause of deadly diarrhoea in children around the world. Globally, the partnership will contribute to Gavi’s immunisation coverage and equity goals and RB’s target of removing diarrhoea as a top-5 cause of infant mortality by 2020.
For more information about RB, please visit www.rb.com.
Contributions and pledges in total: